A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients.
J Clin Exp Hepatol
; 12(3): 735-744, 2022.
Article
in En
| MEDLINE
| ID: mdl-35677522
ADV, Adefovir dipivoxil; ALT, Alanine aminotransferase; CHB, Chronic hepatitis B; EOT, End of treatment; GZ, Grey zone; HBeAg, Hepatitis B e antigen; HBsAg, Hepatitis B surface antigen; HCC, Hepatocellular Carcinoma; HNCH, HBeAg-negative chronic infection; NA, Nucleot(s)ide analogue; ROC, Receiver operating characteristic; TAF, Tenofovir alafenamide fumarateor; TDF, Tenofovir disoproxil fumarate; ULN, Upper limit of normal; UMC, University Medical Centers; combination therapy; functional cure; hepatitis B virus; inactive carrier; low viral load; peg-IFN, Pegylated-interferon
Full text:
1
Database:
MEDLINE
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
J Clin Exp Hepatol
Year:
2022
Type:
Article
Affiliation country:
Netherlands